|

Immunotherapy for Hepatocellular Carcinoma

RECRUITINGSponsored by The First Affiliated Hospital with Nanjing Medical University
Actively Recruiting
SponsorThe First Affiliated Hospital with Nanjing Medical University
Started2024-03-01
Est. completion2026-12-31
Eligibility
Age18 Years+
View on ClinicalTrials.gov →

NCT06241326

Summary

This study is an observational real-world research conducted on Chinese hepatocellular carcinoma (HCC) patients. Its primary objective is to evaluate the safety and efficacy of immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions.

Eligibility

Age: 18 Years+
Inclusion Criteria:

1. Aged after 18 years (18 is included).
2. Hepatocellular carcinoma diagnosed by pathology or imaging.
3. Patients assessed by researchers as potentially benefiting from receiving immunotherapy-based combination regimens.
4. For participants who have previously received treatment according to this protocol, a comprehensive pre-treatment assessment is required, including demographic information, tumor history, medical history, and baseline imaging examinations.
5. Patients voluntarily enroll in this study.

Exclusion Criteria:

1. Pregnant or lactating women.
2. Other conditions regimented at investigators' discretion.

Conditions5

CancerHepatocellular CarcinomaImmunotherapyLiver CancerLiver Disease

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.